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Introduction
The reported incidence of placenta accreta varies widely
in the English literature, from 1:540 to 1:93,000 deliveries
[1]. In Taiwan, the quoted incidence ranges from 1:625
to 1:1,652 deliveries in tertiary medical centers [2–5].
Of patients with this abnormality, the reported frequency
of placenta accreta is approximately 84%, of placenta
increta is 13%, and of placenta percreta is 3% [6]. How-
ever, at Taichung Veterans General Hospital (TVGH),
the incidence is 1:625 deliveries, and the frequency of
placenta accreta is 53.2%, of placenta increta is 29.8%,
and of placenta percreta is 17%. The higher proportion
of placenta increta/percreta in TVGH compared with
that reported in the literature reflects the hospital’s
status as a high-risk referral tertiary medical center.
Massive obstetric hemorrhage is still the leading
cause of pregnancy-related death, and placenta previa
accreta remains one of the major predisposing factors.
With the increasing rates of cesarean delivery and uter-
ine curettage for abortion, both placenta previa and ac-
creta are steadily increasing in frequency. Therefore,
more cases of placenta previa accreta can be expected
in obstetric practice. In several recent series, placenta
accreta has emerged as the major indication for peripar-
tum hysterectomy, accounting for 40% to 60% of cases
[7]. It has, therefore, become a challenging problem of
increasing clinical significance in obstetrics.
Placenta Previa Percreta: A Matter of
Life and Death
Placenta previa percreta is a rare and possibly cata-
strophic obstetric condition. It is the most dangerous
form of invasive placentation because it is potentially
life threatening and poses a serious risk for spontaneous
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uterine rupture as well as massive maternal hemorrhage
due to well-vascularized placental tissue invading the
friable lower uterine segment. In addition, the surgical
vesicouterine mobilization-repair procedure is difficult
and problematic.
Appropriate management of placenta previa increta/
percreta represents an issue of critical concern to
obstetricians. O’Brien et al reported a maternal mortali-
ty rate of 7% (8/109) related to profound blood loss in
patients with placenta percreta; four maternal deaths
(50%) occurred at more than 35 weeks’ gestation, while
the others occurred at 22, 31, and 32 weeks [8]. There-
fore, it is clear that early antenatal diagnosis and appro-
priate perinatal management strategies are crucial to
achieve a good outcome.
Anecdotal Case Reports in Taiwan
Liu et al reported undiagnosed placenta percreta causing
uterine rupture with fatal hemoperitoneum at 22 weeks
of gestation in an in vitro fertilization case (personal
communication, 1986). Another patient with placenta
previa percreta and bladder involvement survived after
two major surgical procedures and massive blood
transfusions at 39 weeks of gestation despite total
estimated blood loss (EBL) of 47,000 mL. Lu et al
reported a similar case with EBL of 25,000 mL at 28
weeks’ gestation [2]. Recently, Shih et al [9] and Chen
et al [10] reported two multipara cases with placenta
previa increta/percreta in which hysterectomy was
performed at 15 weeks of gestation due to episodes of
antepartum hemorrhage with massive blood loss of
12,000 mL and 5,450 mL, respectively, during surgery.
These two case reports showed that even when hys-
terectomy was performed in early pregnancy, the sur-
gical procedure was bloody and problematic. Surgical
access to the lower uterine blood supply demands
preliminary separation of the densely adherent bladder
from the lower uterine segment, compromised by
scarring from previous operations and friable and well-
neovascularized invading placental tissue. This shows
that life-threatening bleeding may ensue from difficult
surgery for placenta previa percreta, even though the
diagnosis has been made in the first or early second
trimesters and well-planned surgery is performed remote
from term.
These case reports raised concern about the need
to promote the importance of accurate early diagnosis
of placenta previa accreta and the methods for achiev-
ing appropriate perinatal management because most
obstetric practitioners lack the expertise to achieve a
sufficient standard of care.
Prenatal Ultrasonographic Diagnosis of
Placenta Previa Accreta
Ultrasonography (US) is a useful tool in screening for
placenta previa accreta. Previous reports have empha-
sized B-mode gray-scale US findings, such as loss of
the normal subplacental anechoic zone, pulsatile flow
into sonolucent placental vascular lakes, abnormal
bladder–uterine wall interphase with thinning, and
disruption and/or focal nodular projections of the linear
hyperechoic boundary echo (Figure 1A) [7,11–14]. These
features are adequate to evaluate most abnormally
adherent placentas.
Traditionally, the location of the abnormally adherent
placenta determines which imaging modality is best
suited for the most specific diagnosis. Most authors
recommend a transabdominal approach to screen for
placenta previa accreta through a semidistended bladder
because anterior placentas are easier to evaluate than
posterior placentas due to decreased penetration and
acoustic shadowing from the fetus. In cases of posterior
placenta previa, magnetic resonance imaging appears
to provide a more confident diagnosis. Other authors
have utilized a transvaginal technique with either an
empty or semidistended bladder in the first or early
second trimester. For patients with an anterior placenta
previa and a suspicious area outside the range of the
transvaginal probe, transabdominal ultrasound is the
best method of diagnosis. Therefore, at TVGH, we use
the transabdominal approach to diagnose placenta
previa accreta in the second and third trimesters.
Transvaginal scanning with the bladder semidistended
to provide better delineation of the uterine serosa–
bladder wall boundary zone is most suitable for the first
trimester scan because abnormal trophoblastic
development in placenta previa accreta with associated
hypervascularity can occur very early after implantation
(Figure 2).
Finberg and Williams found that gray-scale US had
a sensitivity of 93% (14/15) and a specificity of 79%
(15/19) in the diagnosis of placenta accreta [14]. Others
have emphasized color Doppler imaging (CDI) and
power Doppler US as very useful adjuncts in diagnosis
[15–22]. The CDI criteria suggestive of placenta previa
accreta include: diffuse lacunar flow pattern showing
diffusely dilated vascular channels scattered throughout
the whole placenta and the surrounding myometrial or
cervical tissues, and high-velocity pulsatile venous-type
flow in the sonolucent vascular spaces; focal lacunar
flow pattern showing irregular sonolucent vascular lakes
with turbulent lacunar flow distributed regionally or
focally within the intraparenchymal placental area;
interface hypervascularity with abnormal blood vessels
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linking the placenta to the bladder, with low-resistance
arterial blood flow; markedly dilated peripheral sub-
placental vascular channels with pulsatile venous-type
flow over the uterine cervix; and no subplacental vas-
cular signal in the areas lacking the peripheral subpla-
cental hypoechoic zone (Figure 1B) [21]. Characteris-
tic CDI observations in patients who are not thought
to have accreta include: discrete branching of surface
chorionic arteries and intraplacental villous arteries
clearly visualized within the homogeneous placental
substance, with typical flow velocity waveforms;
centrocotyledonary sonolucent avillous cavities
containing a non-pulsatile low-velocity venous flow
(< 8 cm/s) pattern identified by real-time imaging; and
normal subplacental venous complex with non-pulsatile
low-velocity venous blood flow waveforms [21]. The
reported sensitivity of two-dimensional (2D) CDI in
diagnosing placenta previa accreta ranges between
82.4% and 100%, and the specificity ranges between
92% and 96.8% [19,21].
Therefore, gray-scale US and 2D CDI are the primary
diagnostic screening tools. However, neither modality
predicts the degree of bladder invasion in placenta
percreta nor gives an accurate assessment of the scope
of quantitative uteroplacental neovascularization. At
TVGH, we have attempted to use three-dimensional
(3D) color power Doppler imaging to assess quantitative
uteroplacental neovascularization and predict the extent
of bladder invasion in placenta previa increta/percreta
[23,24]. The true value of 3D CDI and angiohistogram
imaging lies in the ability to allow screening through the
targeted region of interest and surrounding the spatial
vascular network architecture, and to simultaneously
analyze aberrant vasculature with different visual
perspectives from sagittal, coronal, and axial scanning
planes. Niche-mode display has been used to demon-
strate the aberrant uteroplacental vessels over the
anatomic area of interest. The stored volume is resliced
in a number of parallel planes until the area of neo-
vascularization is detected within the uterine serosa–
bladder junctional zone. These viewing planes can be
arbitrarily manipulated to better delineate the exact
location and depth of bladder invasion by the aberrant
Figure 1. (A) Transabdominal gray-scale scan showing multiple
large irregular sonolucent spaces traversing the entire placenta.
(B) Conventional 2D color Doppler imaging showing abnormal
lacunar flow pattern. (C) 3D color power Doppler imaging
further defines the abnormal uteroplacental hypervascularity.
B = bladder; H = head; P = placenta.
Figure 2. Transvaginal color Doppler scan at 11 weeks’ gestation
showing uteroplacental hypervascularity. B = bladder; CX =
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placental–myometrial vessels [23–25]. Since the mor-
tality and morbidity associated with placenta previa
percreta increase significantly with the degree of bladder
invasion, correct prenatal diagnosis is crucial for appro-
priate management and surgical planning. Hence, 3D
CDI may be a complementary tool to improve diag-
nostic confidence in characterizing the exact site, extent
of involvement, and depth of aberrant vessel invasion
throughout the object of interest by providing a more
objective method; it is helpful for aiding clinical decision
making and guiding appropriate management plans
[23–25].
Recently, at TVGH, we have studied the clinical
application of 3D imaging for virtual and augmented
reality in placenta previa accreta to the planning and
guidance of perinatal management. The focus was on
the introduction and validation of new maternal–fetal
medical image analysis and image-guided interventional
methodology into obstetric practice. Modeling and
simulation of 3D in uteroplacental–fetal and maternal
bladder spatial anatomic atlases based on tomographic
images play an increasingly important role in appropriate
planning of interventions and simulation of surgical
procedures using 3D models as surgical simulators. 3D
US imaging provides accurate and quick detection of
abnormal uteroplacental neovascularization associated
with instructive visual imaging effect. At TVGH, parents
with placenta accreta are provided with clear “photo-
graphic” images of uteroplacental hypervascularity
disorders so that the obstetrician can evaluate the
angioarchitecture at different angles, giving a clear
“plastic” impression of the severity of the placenta
previa accreta to the parents (Figure 1C).
Finally, it must be emphasized that the three US
screening techniques for antenatal diagnosis of invasive
placenta (gray-scale, 2D CDI and 3D color power
Doppler) appear to be complementary rather than
competitive, and are not mutually exclusive.
Diagnostic Pitfalls
Bladder varices, possibly due to neovascularized vessels
from previous cesarean deliveries, are easily mistaken
for abnormal bladder–uterine serosa interface hypervas-
cularity assumed to be placenta accreta [21]. There-
fore, in patients with findings suggestive of interface
hypervascularity, CDI must clearly demonstrate that
there are abnormal blood vessels linking the placenta to
the bladder. Posterior and lateral uterine wall invasion
are difficult to evaluate with US, particularly in twin
pregnancies. CDI diagnostic errors are often due to sha-
dowing by fetal parts and separate placenta location.
Therefore, Levine and colleagues suggest that in patients
with posteriorly implanted placenta at-risk for accreta,
magnetic resonance imaging should be used when US
cannot rule out the presence of accreta [19]. Other
diagnostic pitfalls include aberration of venous drainage
from the placenta, which is a rare condition. On gray-
scale imaging, blood is observed moving in the marked-
ly dilated subplacental vascular channels in a sluggish
manner. Power Doppler reveals spiral arteries crossing
the lakes to the fetal cotyledons. Failure of the draining
process may have been brought about by local venous
obstruction or perhaps varicosities (Figure 3).
The placenta in abdominal pregnancy and rudi-
mentary horn pregnancy should also cause concern
[21]. Abdominal pregnancy is considered a form of pla-
centa accreta because the placenta does not deliver
spontaneously. According to Benirschke [26], the pla-
cental floor lacks decidua and a large vascular supply
supports the intervillous circulation. CDI studies of one
patient with term abdominal pregnancy show placental
tissue impinging on the urinary bladder simulating
placenta previa; placental hypervascularization was
detected by transabdominal color Doppler US [21].
These sonographic features confirm that extraordina-
ry local vascular development of placental circulation
occurs in abdominal pregnancy. Therefore, the sono-
grapher should carefully search for a displaced uterus
elsewhere if placenta previa accreta is suspected.
Placenta accreta in a rudimentary horn pregnancy
was reported for the first time by Heinonen in 1983
[27]. In a MEDLINE review by Basbug et al [28], of the
Figure 3. A rare condition, aberrant venous drainage from the
uncomplicated placenta previa, can be mistaken for placenta
previa accreta. Color Doppler imaging shows blood moving in
markedly dilated subplacental vascular channels in a sluggish
manner and spiral arteries crossing the vascular lakes to the
fetal cotyledons. Failure of the draining process may have been
brought about by local venous obstruction or perhaps
varicosities. B = bladder; CX = cervix; P = placenta.
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51 cases with rudimentary horn pregnancies, seven were
associated with placenta accreta (13.7%), suggesting
that rudimentary horn pregnancy is more likely to be
associated with placenta accreta than intrauterine
pregnancy. In a study at TVGH, we encountered one
case of term pregnancy in the rudimentary horn of an
unicornuate uterus. The characteristic CDI features
were multiple areas of placenta implantation with a
diffuse-type lacunar flow pattern. [21,29].
Management of Placenta Previa Accreta:
Operative and Conservative Strategies
What perinatal management strategies should be
adopted when prenatal diagnosis has been made?
Ideally, delivery should be elective at the gestational age
of proven lung maturity. Often, however, bleeding will
prompt earlier surgical intervention. Therefore, the
timing of cesarean hysterectomy should be decided
according to hemodynamic morphologic features found
on CDI. It may be appropriate to consider elective
cesarean hysterectomy at 34 weeks’ gestation or even
earlier, irrespective of fetal lung maturity, in patients
with diffuse lacunar flow pattern, particularly associated
with strong evidence of extensive placenta increta/
percreta and episodes of antepartum hemorrhage, in
order to decrease the risk of maternal morbidity and
mortality associated with emergency surgery [21].
Surgical strategies for managing placenta percreta in
late pregnancy have been plagued by massive bleed-
ing, massive transfusion, and immediate or delayed
hysterectomy. However, for patients with a focal lacunar
flow pattern, uneventful cesarean hysterectomy can
usually be performed at more advanced gestation (35–
37 weeks’ gestation). Further studies are necessary to
validate these suggestions.
If CDI shows a diffuse lacunar flow pattern and
bladder–uterine serosa interface hypervascularity,
urologic assessment, including cystoscopy and pre- or
intraoperative placement of a ureteral stent, should be
considered. Cesarean hysterectomy as described by
Catanzarite et al [7] and Pelosi et al [30] should be
used. If large engorged blood vessels are seen within
the visceral peritoneum covering the lower uterine seg-
ment, extending to the top of the bladder, a high fundal
classical incision should be performed at least 2 cm
above the upper margin of adherent placenta to avoid
injuring the hypervascular region in the friable lower
uterine segment. At TVGH, we attempted to remove the
abnormally adherent placenta in one case because of
lack of clinical experience; this caused massive vagi-
nal bleeding at more than 800 mL/minute. The uterine
blood invisibly drained away from the vagina, down the
operating table, and the delivery floor was flooded with
blood, causing a life-threatening hemorrhagic compli-
cation [21]. This painful experience showed that if the
combination of CDI findings and clinical uterine hyper-
vascularity appearance during surgery is highly sug-
gestive of placenta previa accreta, the placenta should
not be removed because, if the involved cotyledon, par-
ticularly if located in the friable lower segment, is ei-
ther pulled off the myometrium with perhaps somewhat
excessive bleeding from that part of the implantation
site or is torn from the placenta, bleeding will increase
immediately or later [21]. During hysterectomy, if
indicated, we sometimes use intentional cystotomy at
TVGH and place two fingers downward to guide the
dissection of the adherent bladder wall and apply the
Penrose drain tourniquet technique to compress the
lower uterine segment in an attempt to reduce blood
flow to the uterus. Furthermore, a ureteral stent passage
is often made preoperatively (via cystoscopy) or intra-
operatively (via cystotomy) to facilitate recognition of
the ureters, potentially preventing injury to the ureter
and the trigone of the bladder.
Prophylactic perioperative balloon occlusion and
embolization of the internal iliac arteries can be used
to attempt to reduce intraoperative blood losses and
facilitate surgery in patients with an ultrasonographic
diagnosis of placenta previa percreta associated with
extensive neovascularization in late viable gestation. It
is essential to establish a stable occluding catheter posi-
tion before entering the operating room. The balloons
are only inflated after classical cesarean delivery, and
it is mandatory to perform the embolization before de-
flating the balloon, to obtain better control of postpar-
tum hemorrhage caused by extensive pelvic collateral
circulation [31,32]. Another technique used to reduce
intraoperative blood loss is two-stage conservative
management (hysterectomy at 2–4 weeks postpartum)
[33].
From the clinical standpoint, early antepartum rec-
ognition of placenta percreta with bladder involvement
is extremely important because patients can receive
appropriate counseling regarding the potential risk of
uterine rupture with fatal hemoperitoneum or life-
threatening hemorrhage in late pregnancy. Timely
pregnancy termination before fetal viability in well-
selected severe cases with no further desire for child-
bearing is appropriate because of decreased morbidity
and mortality.
Recently, transarterial embolization (TAE) has been
chosen at TVGH rather than balloon occlusion cathe-
terization, to attempt to decrease intraoperative blood
loss and facilitate surgery in patients with ultrasono-
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graphic diagnosis of placenta previa percreta in early
gestation. TAE helps to localize the site of hyper-
vascularity. Embolization can also be performed as
selectively as possible in the uterine arteries and other
supplying anastomotic new blood vessels when necessary
(Figure 4). Among six patients with placenta increta/
percreta undergoing hysterectomy with preoperative
prophylactic internal iliac artery embolization (IIAE),
the procedure was associated with an apparent reduc-
tion in mean EBL (1,767 ± 1,213 mL) compared with
two non-embolized patients (4,950 ± 1,061 mL; p =
0.0442). Patients undergoing embolization required
fewer transfusions (4.33 ± 4.08 vs 16.50 ± 4.95; p =
0.043) [6]. This limited experience is encouraging
because of the apparent reduction in operative blood
loss after prophylactic IIAE. These preliminary find-
ings are based on a small number of patients and, there-
fore, further investigation is needed to determine the
effectiveness of this procedure.
Intrapartum and Postpartum Management
of Abnormally Residual Adherent Placenta
As placenta accreta might not be diagnosed antepar-
tum or during labor, especially when no risk factors are
present, adequate preparations cannot be made. The
intrapartum and postpartum management of adherent
placenta remains controversial. Potential complications
include hemorrhage, infection, and persistent placental
tissue. Although hysterectomy remains the recommend-
ed treatment for most patients, uterine conservation is
justified in certain well-selected, non-bleeding cases
where future child-bearing is strongly desired. Such con-
servative management options may include adjuvant
methotrexate (MTX) treatment, curettage, tamponade
of the placental implantation site with inflated Foley
catheter bags, local excision, and repair or oversewing
of the implantation site.
If placenta accreta is diagnosed at the time of cesa-
rean section, two-stage conservative management
intrapartum, with the abnormally adherent placenta
left in situ after delivery, particularly in conditions of
invasive placentation with extension into the blad-
der or gastrointestinal tract and when the operating
obstetrician lacks experience in pelvic dissection, is
thought to be appropriate to avoid the risk of severe
hemorrhage at the time of cesarean delivery. Hyster-
ectomy, bladder wall resection, and reimplantation of
ureters are made technically easier, less bloody, and are
achieved with fewer complications when performed
postpartum compared with the situation when the
same surgical procedures are performed at cesarean
Figure 4. Selective anterior oblique angiogram of the left
internal iliac artery shows: (A) extensive uteroplacental hyper-
vascularity before embolization; (B) no visible flow into the
uterine artery and other supplying parasitized collaterals after
embolization.
section. However, elective hysterectomy ought to be
considered earlier (2–4 weeks postpartum) than sug-
gested in the literature, to avoid development of further
complications, including coagulopathy and an increased
risk of severe genital tract infection or hemorrhage [33].
Medical treatment of residual adherent placenta
with MTX is still controversial. Some authors advocate
leaving the placenta in situ in selected hemodynamically
stable patients when blood loss is minimal and total
hysterectomy is difficult and problematic [34–36]. MTX
affects placental tissue by reducing its vascularity, lead-
ing to its necrosis, separation, and expulsion. Adjuvant
MTX may help in expediting the absorption of the resi-
dual placenta, which should reduce the risk of severe
complications of late postpartum hemorrhage. Even
though MTX treatment seems to reduce blood flow
within the placenta, transcervical removal of the firmly
adherent placenta should not be attempted because
of the risk of potentially profuse hemorrhage, unless
necrotic fragments of the placenta are spontaneously
expelled. Recently, a case was referred to TVGH from a
local medical center, with residual adherent placenta at
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partum management with a firmly adherent placenta
(6 × 7 × 7 cm) left in situ (implanted in the lower segment
of the uterus). After admission, intravenous cefazolin
and gentamicin were given. MTX (1 mg/kg) was injected
intramuscularly on the 25th and 39th postpartum days.
Unfortunately, severe complications of sepsis developed
due to leukopenia (white blood cell count dropped
from 7.08 × 109/L to 0.2 × 109/L). Hysterectomy was
performed 48 days after cesarean delivery. The patient
has gradually recovered from the sequelae of sepsis 4
months after cesarean delivery.
The number of reported cases of residual adherent
placentas successfully treated with MTX is small and the
outcome is uncertain. Therefore, it is unclear whether
this treatment is applicable in the expectant management
of placenta previa percreta [37].
Future Aspects
Although the pathogenesis of placenta accreta is well
characterized at the macroscopic (e.g. uteroplacental
hypervascularity in the region of interest) and microsco-
pic levels (e.g. decidual defect and intramyometrial
infiltration of the placental villous tissue), the molecular
basis of this disorder remains largely unexplored. The
decidual defect in placenta accreta, a common histologic
finding, is usually caused by previous cesarean section
or uterine curettage. Due to the decreased production
of tissue inhibitors of metalloprotease and transforming
growth factor-beta resulting from decidual maldevelop-
ment, the proliferation, migration, and invasiveness of
trophoblasts might be changed significantly. From a
preliminary molecular study at TVGH, we acknowledge
that decidual defect is a major contributing factor to
the formation of placenta accreta. However, epidermal
growth factor receptor (EGFR) and c-erbB-2 expres-
sion in the syncytiotrophoblast may play an additive or
synergistic role. Expression of EGFR and c-erbB-2 in the
villous and extravillous cytotrophoblasts is less likely to
contribute to the development of placenta accreta [38].
Toward the Goal, Press On
Early antepartum identification of placenta accreta/
increta/percreta offers the opportunity for termination
of a life-threatening pregnancy or alteration in the sur-
gical approach to achieve a planned delivery with the
use of internal iliac artery balloon occlusion techniques
in viable late pregnancy and/or IIAE for non-viable
pregnancy in the first and early second trimesters, thus
diminishing blood loss, morbidity, and mortality. First-
trimester diagnosis should therefore be pursued ag-
gressively in any woman with placenta previa and a
history of previous uterine surgery [39].
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